Replies to post #420101 on Amarin Corp Plc (AMRN)

[Johnniegalan]

tats……now you’re asking the right question…esp. given possibility of price cuts in the States…..what does he know about future order flow in Europe and ROW….think China?……he is confident in future cash flows…we shall see

[the_kube]

Per the press release…

Amarin continues to make progress on reducing operating expenses and managing its cash position and is on track to delivery $40 million of annual savings based on reduction in force announced in July 2023. With the recent cash preservation initiatives, Amarin reiterates its believe that current cash and in vestments and other assets are adequate to support continued operations including the share repurchase programs. We will continue to focus on cash preservation and prudently invest in the right opportunities which are value additive.

In Q3, Amarin reported a net loss of $19.3 million or a loss of $0.05 per share. I suspect 4th quarter earnings will still be negative and cash flow will be near 0.

Is it possible with $6 to $8 million in revenue growth and continued cost discipline, the above statement from the press release is credible?

[Chromosome]

He thinks he can generate enough cash to offset share repurchase

[ziploc_1]

The Q4 2023 report makes clear that Amarin has $300 million plus in cash and a positive cash flow...It also indicates that Amarin has an accepted product(Vascepa) in a vibrant market in the US and in ROW...with significant potential to become a blockbuster drug.